Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 285

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 285
---
 years ended December 31, 2023 and 2022, the Company recorded an income of $5 and an expense of $270,
respectively, for the revaluation of such warrants, within financial expense, net in the statements of comprehensive loss.

A summary of significant unobservable
inputs (Level 3 inputs) used in measuring the fair value of the warrants issued are as follows:

|               |     |   | December 31, 
         2023 |   |     |   | December 31, 
         2022 |   |
|:--------------|:----|:--|-------------:|:--|:----|:--|-------------:|:--|
| Discount rate |     |   |         30.0 | % |     |   |         30.0 | % |
| Term (years)  |     |   |         0.25 |   |     |   |          0.5 |   |
| Fair value    |     | $ |          402 |   |     | $ |          407 |   |

<div align='center'>F-34</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | WARRANT LIABILITY (Cont.) |

The following table presents changes
in the fair value of the warrant liability:

| Balance as of January 1, 2022   |     | $ | 137 |   |
| Changes in fair value           |     |   | 270 |   |
| Balance as of December 31, 2022 |     | $ | 407 |   |
| Changes in fair value           |     |   |  (5 | ) |
| Balance as of December 31, 2023 |     | $ | 402 |   |

The Company has performed a sensitivity
analysis of the warrant liability which is classified as level 3 financial instruments in the fair value hierarchy. The Company recalculated
the value of the warrants by applying a +/- 5.0% changes to the input variables in PWERM. As of December 31, 2023, a 5.0% decrease in
discount rate would increase the fair value of the warrants to $408; a 5.0% increase in discount rate would decrease the fair value of
the warrants to $397.

| NOTE 8:- | TAX